KVD900 Slows HAE Attacks, Quickens Symptom Relief in Phase 2 Trial

KVD900 Slows HAE Attacks, Quickens Symptom Relief in Phase 2 Trial

299485

KVD900 Slows HAE Attacks, Quickens Symptom Relief in Phase 2 Trial

Single, on-demand treatment with the investigational oral medicine KVD900 safely and significantly slowed the progression of swelling attacks and shortened the time to symptom relief and resolution in adults with hereditary angioedema (HAE), according to the latest data from a Phase 2 trial. “HAE patients continue to seek an oral option for on-demand treatment of their disease, to fully manage their disease or for breakthrough attacks for those on prophylaxis,” Emel Aygören-Pürsün, MD, the trial’s…

You must be logged in to read/download the full post.